Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northside Hospital
Atlanta, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- St. Louis Cancer Care
Bridgeton, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jun 2018
- Primary completion
- 15 Nov 2020
- Completion
- 15 Nov 2020
- Last update posted
- 19 Nov 2020
- Registered enrollment
- 38
- Registry id
- NCT03553550
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.